SRPT
HEALTHCARESarepta Therapeutics,, Inc. Common Stock
AI Insight
What's Moving SRPT Today?
No stock-specific AI insight has been generated for SRPT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.68$25.32
$16.39
Fundamentals
Market Cap$1.6B
P/E Ratio44.4
EPS$0.35
Dividend Yield—
Dividend / Share—
ROE4.9%
Profit Margin3.0%
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding105.6M
SRPT News
29 articles- Sarepta Therapeutics (SRPT) Names A New CEO, Is The Stock Cheap?Yahoo Finance·Aug 1, 2026
- ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance·Jul 31, 2026
- Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to DeclineYahoo Finance·Jul 29, 2026
- Leadership changes afoot at two CGT biotechsPharmaceutical-technology·Jul 28, 2026
- Sarepta Therapeutics (SRPT) Brings In New CEO Severino Is Its R&D Strategy Entering a New Phase?Simply Wall St·Jul 28, 2026
- Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive OfficerBioSpace·Jul 28, 2026
- Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term?Stocktwits·Jul 27, 2026
- Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEOBiopharmadive·Jul 27, 2026
- Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?Trefis·Jul 23, 2026
- SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?Yahoo Finance·Jul 22, 2026
- Sarepta Therapeutics to Announce Second Quarter 2026 Financial ResultsYahoo Finance·Jul 22, 2026
- SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne SpaceStocktwits·Jul 21, 2026
- Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne SpaceYahoo Finance·Jul 20, 2026
- uniQure Trends to Watch as Gene Therapy Bets Shift Beyond HemgenixYahoo Finance·Jul 17, 2026
- Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued?Yahoo Finance·Jul 14, 2026
- The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD TherapiesYahoo Finance·Jul 14, 2026
- What It Means To Hold Moderna Stock In A CrashTrefis·Jul 13, 2026
- 2 Beaten-Down Stocks That Still Aren't Worth BuyingThe Motley Fool·Jul 11, 2026
- Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up247 Wall St·Jul 10, 2026
- Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout247 Wall St·Jul 10, 2026
- Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset ValuationSimply Wall Street·Jul 1, 2026
- FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in DuchenneBioPharm International·Jul 1, 2026
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire·Jul 1, 2026
- FDA Accepts Sarepta's Applications for Full Approval of Two DMD TreatmentsIntellectia AI·Jun 30, 2026
- Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsBenzinga·Jun 30, 2026
- Is Sarepta (SRPT) Quietly Recasting Its Story Around siRNA as Elevidys Awaits Regulators?Simply Wall Street·Jun 20, 2026
- Sarepta Therapeutics Adopts 2026 Equity Incentive and Employee Stock Purchase Plans – 8-K SEC Filing SummaryMinichart·Jun 5, 2026
- Rare Disease Therapeutics Market 2025-2033 | Market GrowthopenPR.com·May 18, 2026
- Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?Benzinga·Mar 27, 2026
All 29 articles loaded
Price Data
Open$16.01
Previous Close$15.88
Day High$16.41
Day Low$15.64
52 Week High$25.32
52 Week Low$14.68
52-Week Range
$14.68$25.32
$16.39
Fundamentals
Market Cap$1.6B
P/E Ratio44.4
EPS$0.35
Dividend Yield—
Dividend / Share—
ROE4.9%
Profit Margin3.0%
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding105.6M
About Sarepta Therapeutics,, Inc. Common Stock
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—
Analyst Rating
HOLDTarget $22.17
Strong Buy 0Buy 6Hold 13Sell 3Strong Sell 2
Insider Activity
SEVERINO MICHAEL
Chief Executive Officer
BUY
BEHRENS M KATHLEEN
BUY
Connelly Deirdre P
BUY
Wigzell Hans Lennart Rudolf
BUY
Nicaise Claude
BUY
Chambers Michael Andrew
BUY
Barry Richard
BUY
Mayo Stephen
BUY
© 2026 DailyFinz AI. All rights reserved. AI-generated analysis, not investment advice.